Find clinical trials

The STRIKE clinical trial at the Alfred Hospital tests whether the medication infliximab can reduce lung inflammation in people with advanced silicosis from artificial stone exposure. This study offers hope for a potential treatment for silicosis, a progressive lung disease that currently has no approved therapy.

This proposed study 817P203, is a Phase 2 double-blind, randomised, placebo-controlled, multicentre, parallel-group study to evaluate the efficacy, safety, and tolerability of SPN-817 in adults with focal onset seizures. The study is planned to involve approximately 258 participants aged 18 to 70 years who have focal onset seizures at multiple study sites worldwide in the United States, Europe, and Asia Pacific. The study will have two groups of participants will be randomly assigned in a 2:1 ratio to SPN-817 (3.0 to 4.0 mg twice daily [BID]) or placebo, respectively, to achieve approximately 180 participants globally completing the study. The duration of treatment with SPN-817 or placebo will be approximately 22 to 24 weeks. The Primary Objective is to evaluate the efficacy of SPN-817 as a treatment for adult participants with focal onset seizures. The Secondary Objectives are to evaluate the safety and tolerability of SPN-817 as a treatment for adult participants with focal onset seizures, and to characterize the pharmacokinetics (PK) of huperzine A after multiple dose administrations of SPN-817 (population PK analysis).

This study will use MRI and Ultrasound techniques to help track the health of joints in patients with Haemophilia A taking Efanesoctocog Alfa Prophylaxis. The study will take place over the course of 1 year and will involve up to 5 outpatient visits (plus scans). The Efanesoctocog Alfa will be taken at home via IV (patients/guardians will be trained prior).

The purpose of this study is to compare eftilagimod alfa (efti) in combination with pembrolizumab and chemotherapy versus placebo in combination with pembrolizumab and chemotherapy among adults with metastatic non-small cell lung cancer (NSCLC).

The main aim of this study is to learn if TAK-279 reduces bowel inflammation and symptoms compared to placebo. Another aim is to compare any medical problems that participants have when they take TAK-279 or placebo and how well the participants tolerate any problems.

The participants will take capsules of either TAK-279 or placebo for up to 3 months (12 weeks). Then all the participants will receive TAK-279 for the rest of the treatment part of the study (1 year or 52 weeks).

During the study, participants will visit their study clinic several times.